GC
CERE

Guggenheim Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Guggenheim Capital’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-44,847
Closed -$1.83M – 1961
2024
Q2 		$1.83M Buy
44,847
+19,019
+74% +$792K 0.01% 844
2024
Q1 		$1.09M Buy
25,828
+1,229
+5% +$51.6K 0.01% 1154
2023
Q4 		$1.04M Buy
24,599
+10,177
+71% +$292K 0.01% 1143
2023
Q3 		$315K Buy
14,422
+1,055
+8% +$26.4K ﹤0.01% 1604
2023
Q2 		$425K Buy
13,367
+1,443
+12% +$44.3K ﹤0.01% 1538
2023
Q1 		$291K Buy
11,924
+1,430
+14% +$42K ﹤0.01% 1693
2022
Q4 		$331K Buy
+10,494
New +$296K ﹤0.01% 1641

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Guggenheim Capital's CERE Position: Q3 2024 in Review

Guggenheim Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 44,847 shares — an estimated $1.83M sold.

Guggenheim Capital first reported a position in CERE in Q4 2022 and held it in 7 quarters. The position peaked at $1.83M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Guggenheim Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Guggenheim Capital sold 44,847 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.83M.
  • Guggenheim Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 7 quarters.
  • Guggenheim Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.83M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Guggenheim Capital's 13F filing for Q3 2024, filed 13 Nov 2024.